On December 4, 2024 Flamingo Therapeutics ("Flamingo") reported that an abstract has been selected for presentation at the 66th Annual ASH (Free ASH Whitepaper) Annual Meeting and Exposition, being held in San Diego, CA from December 7-9, 2024 (Press release, Flamingo Therapeutics, DEC 4, 2024, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-poster-presentation-on-aml-phase-1-iit-study-at-ash-2024 [SID1234648788]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, selected for a poster presentation, is a Trials-in-Progress presentation of a Phase 1 investigator-initiated study of danvatirsen monotherapy followed by danvatirsen combination with venetoclax in relapsed/refractory AML and intermediate/high risk MDS (NCT05986240). The study is being conducted at Albert Einstein / Montefiore Medical Center in New York City and MD Anderson Cancer Center in Houston.
Poster presentation details are as follows:
Title: "A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed by Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML"
Session Date: Monday, December 9, 2024
Presenting Author: Dr. Aditi Shastri